Nasdaq OMX

Apricus Biosciences, Inc.

26.7.2017 13:02 | Nasdaq OMX

Del

Apricus Biosciences Announces Corporate Update and Second Quarter 2017 Financial Results Conference Call

SAN DIEGO, July 26, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Apricus' second quarter 2017 financial results will be released on Wednesday, August 2, 2017 at 4:01 p.m. Eastern Time.  Company management will host a conference call on Wednesday, August 2, 2017 at 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.

To participate by telephone, please dial (855) 780-7196 (Domestic) or (631) 485-4867 (International).  The conference ID number is 58725002.  The live audio webcast can be accessed via the Investor Relations' section of Apricus' website at www.apricusbio.com .  Please log in approximately 5-10 minutes before the event to ensure a timely connection.  The archived webcast will remain available for 30 days following the live call.

About Apricus Biosciences, Inc .

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates currently in development.  Vitaros is a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan). RayVa is our product candidate in Phase 2 development for the treatment of the circulatory disorder Raynaud's phenomenon, secondary to scleroderma, for which Apricus owns worldwide rights.

For further information on Apricus, visit http://www.apricusbio.com .

Vitaros(TM)  is Apricus' trademark in the United States, which is pending registration and subject to the agreement with Allergan.  Vitaros®  is a registered trademark of Ferring International Center S.A. in certain countries outside of the United States.  RayVa(TM)  is Apricus' trademark, which is registered in certain countries throughout the world and pending registration in the United States. 

CONTACT: 
Institutional / Retail Investors: Matthew Beck
mbeck@troutgroup.com
The Trout Group LLC
(646) 378-2933


WEB:http://www.apricusbio.com

Information om Nasdaq OMX

Nasdaq OMX
Nasdaq OMX
Nikolaj Plads 6
1007 København K

+45 3377 0377http://globenewswire.com